Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome. The new CAB brings unparalleled expertise in basement membrane biology, genetic kidney diseases, and glomerular disorders, providing critical guidance as Fibrocor advances its first-in-class pipeline towards […]
